MY129445A - Compositions for treating inflammatory response - Google Patents

Compositions for treating inflammatory response

Info

Publication number
MY129445A
MY129445A MYPI20000343A MYPI20000343A MY129445A MY 129445 A MY129445 A MY 129445A MY PI20000343 A MYPI20000343 A MY PI20000343A MY PI20000343 A MYPI20000343 A MY PI20000343A MY 129445 A MY129445 A MY 129445A
Authority
MY
Malaysia
Prior art keywords
compositions
inflammatory response
treating inflammatory
compounds
methods
Prior art date
Application number
MYPI20000343A
Other languages
English (en)
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
Macdonald Timothy
Okusa Mark
Irving L Kron
Scheld W Michael
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Publication of MY129445A publication Critical patent/MY129445A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20000343A 1999-02-01 2000-01-31 Compositions for treating inflammatory response MY129445A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
MY129445A true MY129445A (en) 2007-04-30

Family

ID=27557920

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20000343A MY129445A (en) 1999-02-01 2000-01-31 Compositions for treating inflammatory response

Country Status (25)

Country Link
EP (1) EP1150991B1 (https=)
JP (1) JP4837831B2 (https=)
KR (1) KR100668006B1 (https=)
CN (1) CN1191266C (https=)
AR (1) AR029332A1 (https=)
AT (1) ATE263777T1 (https=)
AU (2) AU778870B2 (https=)
BR (1) BR0007864A (https=)
CA (1) CA2361614C (https=)
CZ (1) CZ296404B6 (https=)
DE (1) DE60009665T2 (https=)
DK (1) DK1150991T3 (https=)
EE (1) EE05185B1 (https=)
ES (1) ES2215609T3 (https=)
HU (1) HU228937B1 (https=)
IL (2) IL144188A0 (https=)
MX (1) MXPA01007850A (https=)
MY (1) MY129445A (https=)
NO (1) NO321216B1 (https=)
NZ (1) NZ513096A (https=)
PL (1) PL199953B1 (https=)
PT (1) PT1150991E (https=)
SK (1) SK284877B6 (https=)
UA (1) UA72912C2 (https=)
WO (1) WO2000044763A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
CA2563123A1 (en) * 2004-04-02 2005-10-20 Adenosine Therapeutics, Llc Selective antagonists of a2a adenosine receptors
WO2005107463A1 (en) * 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2007120972A2 (en) 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
AU2007263728A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN102119023B (zh) 2008-07-03 2014-04-09 弗吉尼亚大学专利基金会 阿帕地松单位剂量
EA201270102A1 (ru) 2009-06-30 2012-08-30 Форест Лэборетериз Холдингз Лимитед Соединения алкокси-карбонил-амино-алкинил-аденозина и их производные в качестве агонистов ar
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
JP2022538410A (ja) * 2019-06-21 2022-09-02 アカデミー オブ ミリタリー メディカル サイエンシズ Ａ２ａアデノシン受容体拮抗作用を有する小分子化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
US5270304A (en) * 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
KR920700218A (ko) * 1989-06-20 1992-02-19 원본미기재 2-알키닐 아데노신의 합성중간체, 그 합성 중간체의 제조법, 그 합성중간체를 이용한 2-알키닐 아데노신의 제조법 및 안정한 2-알키닐 아데노신 유도체
WO1991009864A1 (fr) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Medicament pour le traitement d'affections ischemiques du c×ur ou du cerveau
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
WO2000044763A3 (en) 2000-12-14
CN1191266C (zh) 2005-03-02
JP2002536300A (ja) 2002-10-29
CA2361614E (en) 2000-08-03
EP1150991B1 (en) 2004-04-07
ES2215609T3 (es) 2004-10-16
NO321216B1 (no) 2006-04-03
SK284877B6 (sk) 2006-01-05
WO2000044763A2 (en) 2000-08-03
NO20013507L (no) 2001-09-18
EP1150991A2 (en) 2001-11-07
NZ513096A (en) 2003-01-31
BR0007864A (pt) 2001-11-06
AU2745400A (en) 2000-08-18
CN1357002A (zh) 2002-07-03
AU778870B2 (en) 2004-12-23
HK1047288A1 (en) 2003-02-14
HUP0200224A2 (en) 2002-06-29
CA2361614A1 (en) 2000-08-03
CA2361614C (en) 2008-08-26
HU228937B1 (en) 2013-06-28
HUP0200224A3 (en) 2005-02-28
DE60009665D1 (de) 2004-05-13
PT1150991E (pt) 2004-08-31
DE60009665T2 (de) 2004-08-19
JP4837831B2 (ja) 2011-12-14
UA72912C2 (uk) 2005-05-16
CZ20012781A3 (cs) 2002-01-16
KR100668006B1 (ko) 2007-01-15
AU2005201255A1 (en) 2005-04-21
IL144188A (en) 2008-12-29
IL144188A0 (en) 2002-05-23
AU2005201255B2 (en) 2008-02-28
EE05185B1 (et) 2009-06-15
DK1150991T3 (da) 2004-06-07
EE200100397A (et) 2002-08-15
ATE263777T1 (de) 2004-04-15
CZ296404B6 (cs) 2006-03-15
KR20020013494A (ko) 2002-02-20
AR029332A1 (es) 2003-06-25
NO20013507D0 (no) 2001-07-13
SK10972001A3 (sk) 2002-01-07
MXPA01007850A (es) 2002-08-20
PL199953B1 (pl) 2008-11-28

Similar Documents

Publication Publication Date Title
MY129445A (en) Compositions for treating inflammatory response
BR9810342A (pt) Novos compostos imidazola substituìdos
EP1112070A4 (en) NEW SUBSTITUTED TRIAZOLE COMPOUNDS
HUP0200749A3 (en) Substituted benzimidazoles and their use as parp inhibitors and process for their preparation
PT1189916E (pt) N-pirazole agonistas do receptor a2a
IL142132A0 (en) Methods and compositions for treating receptor mediated diseases
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
TR199801360T2 (xx) Yeni ikameli imidazol bile�imleri.
MY119800A (en) Pyridine derivatives
BR9706973A (pt) Novos compostos de imidazol substituídos
GB9823873D0 (en) 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
NZ326331A (en) Heterocycle-condensed morphinoid derivatives and medicaments
AU2003243373A8 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
TR200002345T2 (tr) Glukokortikoit seçiçi antienflamatuar ajanlar
IS5815A (is) Setin 1,8-naftýridín-4(1H)-ón sem fosfódíesterasa4 latar
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
PT1622908E (pt) Derivados de xantina como antagonistas do receptor a2b de adenosina
DE59800439D1 (de) Vernetzbare, in Wasser redispergierbare Pulverzusammensetzung
AU3812401A (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
WO2001060350A3 (en) Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
MXPA01011923A (es) Composiciones y metodos para tratar alteraciones en la proliferacion celular.
IL144031A0 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
UA84404C2 (ru) Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина